In human prostate cancer, it has been shown that GSK3α is mainly expressed in low-risk prostate cancers and is associated with hormone-dependent androgen receptor (AR)-mediated gene expression, whereas GSK3β is mainly expressed in high-risk prostate cancers and is associated with hormone-independent AR-mediated gene expression [49, 50]. The gene discussed is GSK3A; the disease is prostate carcinoma.